Compare ASE Technology Holding Co Ltd (ASX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Recursion Pharmaceuticals Inc — how do they compare? ASE Technology Holding Co Ltd trades at $39 (market cap $101.68B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: ASE Technology Holding Co Ltd is far larger — about 57.1× Recursion Pharmaceuticals Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ASX | RXRX | |
|---|---|---|
Market Cap | $101.68B | $1.78B |
Sector | Technology | Health |
52-Week High | $45.12 | $6.79 |
52-Week Low | $9.63 | $2.84 |
Enterprise Value | $106.08B | $1.30B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $37.39, up 0.38% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, beating estimates of $0.23, and announced a $10.5 billion capital expenditure increase for AI-driven growth (Reuters, July 30, 2026). Revenue rose to $645.39 billion in 2025, with net income of $40.02 billion, while valuation ratios like P/E of 46.26 suggest premium pricing.
Outlook remains positive due to AI semiconductor demand and margin expansion, but risks include high valuation and competitive pressures. Analysts are largely bullish with 80% buy ratings, though the stock faces volatility near resistance at $38.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
